[Aggressive lymphoma (DLBCL, MCL) - what's new?]

Our understanding of the molecular basis of the development and progression of malignant lymphoma has significantly improved over the last decades leading to the identification of genetic alterations with proven prognostic impact on the clinical course of the disease, such as TP53 mutations in MCL. This deepened molecular understanding sets the basis for the current rapid development regarding targeted and immuno-based therapies, offering individualized, risk-adapted treatment strategies in our near future with the potential to further improve patient care.These new therapeutic alternatives are more and more being integrated in first-line treatments of DLBCL and MCL, among others, potentially replacing conventional chemotherapy-based treatment strategies. Yet, despite these promising new developments, clinical courses of patients with primary refractory disease or early relapses (< 12 months) are still characterized by only moderate responses and very limited overall survival even upon treatment with the available targeted treatment alternatives. For such high-risk patients, further optimized and individualized therapeutic strategies are highly warranted.This article summarizes new findings regarding tumor biology and actual developments expanding the therapeutic landscape of DLBCL and MCL.
Competing Interests: Prof. Dreyling gibt an innerhalb der vergangenen 3 Jahre Forschungsunterstützung von Abbvie, Bayer, BMS/Celgene, Gilead/Kite, Janssen, Roche und Vortragshonorare von Amgen, Astra Zeneca Gilead/Kite, Janssen, Lilly, Novartis, Roche erhalten zu haben. Er war in einem Beratungsgremium von Astra Zeneca, BeiGene, BMS/Celgene, Gilead/Kite, Janssen, Lili/Loxo, Novartis, Roche tätig.
(Thieme. All rights reserved.)